Outcomes of percutaneous nephrolithotomy in a resource-limited setting: a retrospective study
Archivio Italiano di Urologia e Andrologia · 31.03.2026 · 98 (1)
DOI: 10.4081/aiua.2026.14940 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archivio Italiano di Urologia e Andrologia, online erschienen am 31.03.2026. Verfasst von Radman Ghaleb und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Faculty of Medicine, Taiz University, Ibb. Hauptthemen laut MEDLINE: Nephrolithotomy, Percutaneous, Resource-Limited Settings, Kidney Calculi. Die Arbeit nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Percutaneous nephrolithotomy (PCNL) is the gold standard for managing large renal calculi; however, data on its long-term efficacy in resource-limited settings such as Yemen are scarce. We evaluated the outcomes and complications of PCNL surgery in resource limited settings over a nine-year period in a high-volume centre in Ibb City, Yemen.
Methods
We conducted a retrospective analysis of 1,458 patients who underwent PCNL between October 2016 and June 2025. Data included patient demographics, stone characteristics, surgical techniques (standard, mini-PCNL, and supine), and outcomes. The stone-free rate (SFR) was defined as the absence of fragments greater than 4 mm on follow-up imaging at three months. Complications were classified using the Clavien-Dindo system.
Results
The cohort comprised 763 (52.3%) males and 695 (47.7%) females with a mean age of 43.8±17.5 years (range: 2-87 years). Staghorn calculi were present in 647 cases (44.4%). Prone lower-pole access was the predominant approach (58.2%), with a progressive institutional shift toward mini-PCNL (5.7%), supine PCNL (3.1%), and ultrasound-guided access (1.4%) in later years. The primary stone-free rate after a single session was 76.0%, increasing to a final SFR of 92.6% following auxiliary interventions including repeat PCNL, ureteroscopy (2.8%), ESWL (1.5%), and conservative management of clinically insignificant residual fragments (6.0%). Major complications (Clavien-Dindo Grade III-V) occurred in 1.44% of cases, including colonic perforation (0.41%) and conversion to open surgery (0.62%). Mortality rate was 0.14% (n=2). Minor complications (Grade I-II) affected 17.4% of patients, predominantly postoperative pain (7.3%) and transient fever (5.3%).
Conclusions
This large series demonstrates that PCNL can be performed with high stone-free rates and acceptable morbidity in resource-limited settings despite a high prevalence of complex staghorn calculi. The progressive adoption of miniaturized and supine techniques reflects institutional adaptability and confirms the feasibility of implementing contemporary endourological standards in low-resource environments.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Faculty of Medicine, Taiz University, Ibb.
- Department of Urology, Faculty of Medicine, Ibb University, Ibb.
Zitieren
APA
Ghaleb, R., Qaid, S., Almashraki, N., Haider, N. A., Al-Shami, E., Musleh, B. M., Muleky, J., & Ahmed, F. (2026). Outcomes of percutaneous nephrolithotomy in a resource-limited setting: a retrospective study. Archivio Italiano di Urologia e Andrologia, 98(1). https://doi.org/10.4081/aiua.2026.14940
Vancouver
Ghaleb R, Qaid S, Almashraki N, Haider NA, Al-Shami E, Musleh BM, et al. Outcomes of percutaneous nephrolithotomy in a resource-limited setting: a retrospective study. Archivio Italiano di Urologia e Andrologia. 2026;98(1). doi:10.4081/aiua.2026.14940
BibTeX
@article{Ghaleb2026,
author = {Ghaleb, Radman and Qaid, Sultan and Almashraki, Noaman and Haider, Nagm Aldean and Al-Shami, Ebrahim and Musleh, Basam Musleh and Muleky, Jamil and Ahmed, Faisal},
title = {Outcomes of percutaneous nephrolithotomy in a resource-limited setting: a retrospective study},
journal = {Archivio Italiano di Urologia e Andrologia},
year = {2026},
volume = {98},
number = {1},
doi = {10.4081/aiua.2026.14940}
}
EUVIMED